.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin caused boosted progression-free and also overall survival, causing FDA commendation and also a new treatment choice for clients.